-- 尽管营收承压，中国太平洋保险（港交所代码：2601，上海证券交易所代码：601601）第一季度净利润仍实现增长。 这家总部位于上海的保险巨头周二晚间向香港联交所提交的公告显示，第一季度净利润同比增长4%，从96亿元人民币增至100亿元人民币。 每股收益从1元人民币降至0.94元人民币。 营收同比下降1.2%，从937亿元人民币降至925亿元人民币。 保险业务收入同比增长1%，从696亿元人民币增至702亿元人民币。 中国太平洋人寿保险业务收入同比增长2.6%，达到216亿元人民币。已收保费同比下降2.8%，从1196亿元人民币降至1163亿元人民币。新增常规保费同比增长41%，达到189亿元人民币。 中国太平洋人寿保险业务新增业务额增长9.6%，达到63.7亿元人民币。 代理渠道保费增长3.2%，从829亿元人民币增至855亿元人民币；而银行保险业务保费则下滑22%，从268亿元人民币降至209亿元人民币。 团体渠道保费小幅下降1.3%，从94.2亿元人民币降至92.9亿元人民币。 财产险业务的初始保费收入下滑0.3%，至630亿元人民币；营业收入下滑0.2%，至478亿元人民币。 周三下午交易时段，中国太平洋人寿保险在香港和上海的股价分别上涨5%和4%。
Related Articles
Equities
RBC Upgrades Tamboran Resources to Outperform From Sector Perform, Raises Price Target to $55 From $38, Keeps Speculative Risk
Tamboran Resources (TBN) has an average rating of buy and mean price target of $57.40 according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$TBN
Asia
Shanghai Pharmaceuticals' Profit Climbs 6.4% in Q1
Shanghai Pharmaceuticals (SHA:601607, HKG:2607) recorded a 6.4% rise in attributable profit in the first quarter of 2026 to 1.42 billion yuan from 1.33 billion yuan a year prior, according to a Wednesday Hong Kong bourse filing.The pharma company's earnings per share rose to 0.3823 yuan from 0.3595 yuan in the corresponding period of the previous fiscal year.Revenue jumped 6.4% to 75.3 billion yuan from 70.8 billion yuan in the year-ago period.
$HKG:2607$SHA:601607
Mining & Metals
CGI Q2 Adjusted Net Earnings $483.4M, up 0.6% YoY
$GIB-A.TO